(Q39819599)

14 September 2017

Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6276906&resulttype=core&format=json

13 May 2020

0 references

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6276906&resulttype=core&format=json

13 May 2020

Enriqueta Felip

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6276906&resulttype=core&format=json

13 May 2020

Øystein Fløtten

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6276906&resulttype=core&format=json

13 May 2020

author name string

M Chatterjee

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6276906&resulttype=core&format=json

13 May 2020

D C Turner

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6276906&resulttype=core&format=json

13 May 2020

H Lena

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6276906&resulttype=core&format=json

13 May 2020

L Horn

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6276906&resulttype=core&format=json

13 May 2020

E B Garon

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6276906&resulttype=core&format=json

13 May 2020

R Hui

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6276906&resulttype=core&format=json

13 May 2020

H-T Arkenau

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6276906&resulttype=core&format=json

13 May 2020

M A Gubens

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6276906&resulttype=core&format=json

13 May 2020

M D Hellmann

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6276906&resulttype=core&format=json

13 May 2020

D Dong

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6276906&resulttype=core&format=json

13 May 2020

C Li

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6276906&resulttype=core&format=json

13 May 2020

K Mayawala

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6276906&resulttype=core&format=json

13 May 2020

T Freshwater

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6276906&resulttype=core&format=json

13 May 2020

M Ahamadi

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6276906&resulttype=core&format=json

13 May 2020

J Stone

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6276906&resulttype=core&format=json

13 May 2020

G M Lubiniecki

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6276906&resulttype=core&format=json

13 May 2020

J Zhang

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6276906&resulttype=core&format=json

13 May 2020

E Im

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6276906&resulttype=core&format=json

13 May 2020

D P De Alwis

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6276906&resulttype=core&format=json

13 May 2020

A G Kondic

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6276906&resulttype=core&format=json

13 May 2020

publication date

26 April 2016

1 reference

14 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6276906&resulttype=core&format=json

13 May 2020

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6276906&resulttype=core&format=json

13 May 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6276906&resulttype=core&format=json

13 May 2020

page(s)

1291-1298

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6276906&resulttype=core&format=json

Population pharmacokinetics of therapeutic monoclonal antibodies

13 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW174

Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW174

Pembrolizumab for the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW174

Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW174

Exploratory modeling and simulation to support development of motesanib in Asian patients with non-small cell lung cancer based on MONET1 study results

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW174

A review of mixed-effects models of tumor growth and effects of anticancer drug treatment used in population analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW174

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW174

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW174

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW174

Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW174

Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW174

PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW174

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW174

Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW174

Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW174

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDW174

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6276906&resulttype=core&format=json

release_msgnaxwnljebtiv25mymiytvse

13 May 2020

Fatcat ID

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6276906&resulttype=core&format=json

13 May 2020

1 reference